Pharmacoepidemiology and rheumatic diseases: 2001-2002

Current Opinion in Rheumatology

Volumn 15, Issue 2, 2003, Pages 122-126

  Solomon, Daniel H ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CYCLOPHOSPHAMIDE; DEFLAZACORT; GLUCOCORTICOID; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANGIONEUROTIC EDEMA; ASEPTIC MENINGITIS; CENTRAL NERVOUS SYSTEM; CHOLESTASIS; DATA BASE; DISEASE ASSOCIATION; DRUG ACCUMULATION; HEART INFARCTION; HUMAN; OSTEOPOROSIS; PANCREATITIS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; TUBERCULOSIS; URTICARIA; VISUAL DISORDER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CYCLOOXYGENASE INHIBITORS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHARMACOEPIDEMIOLOGY; RHEUMATIC DISEASES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0037371675     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200303000-00006     Document Type: Review

References (43)

1. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
2. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
3. Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280-2288.
4. Reicin AS, Shapiro D, Sperling RS, et al.: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002, 89:204-209.
5. White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425-430.
6. Rahme E, Pilote L, Lelorier J: Association between eaproxee use and protection against acute myocardial infarction. Arch Intern Med 2002, 162:1111-1115.
7. Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118-123.
8. Solomon DH, Glynn PJ, Levin R, et al.: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104.
9. Watson DJ, Rhodes T, Cai B, et al.: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105-1110.
10. Schwartz JI, Vandormael K, Malice MP, et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normalsalt diet. Clin Pharmacol Ther 2002, 72:50-61.
11. Zhao SZ, Reynolds MW, Lefkowith J, et al.: A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Center safety database. Clin Therapeutics 2001, 23:1478-1491.
12. White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ace inhibitors. Hypertension 2002, 39:929-934.
13. Alkhuja S, Menkel RA, Alwarshetty M, et al.: Celecoxib-induced nonoliguric acute renal failure. Ann Pharmacother 2002, 36:52-54.
14. Rocha JL, Fernandez-Alonso J: Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001, 357:1946-1947.
15. Woywodt A, Schwarz A, Mengel M, et al.: Nephrotoxicity of selective cox-2 inhibitors. J Rheumatol 2001, 28:2133-2155.
16. Martin-Garcia C, Hinojosa M, Berges P, et al.: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002, 121:1812-1817.
17. Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001, 108:47-51.
18. Szczeklik A, Nizankowska E, Bochenek G, et al.: Safety of a specific cox-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001, 31:219-225.
19. Borges MS, Capriles-Hulett A, Caballero-Fonseca F, et al.: Tolerability to new cox-2 inhibitors in NSAID sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001, 87:201-204.
20. Nettis E, Di Paola R, Ferranninni A, et al.: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002, 88:331-334.
21. Quiralte J, De San Pedro SB, Florido JJF: Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAIDS-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002, 89:63-66.
22. Amaravadi RK, Jacobson BC, Solomon DH, et al.: Acute pancreatitis associated with rofecoxib. Am J Gastroenterol 2002, 97;1077-1078.
23. Nachimuthu S, Volfinzon L, Gopal L: Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001, 77:548-550.
24. Kelkar PS, Butterfield JH, Teaford HG: Urticaria and angioedema from cyclo-oxygenase-2 inhibitors. J Rheumatol 2001, 28:2553-2554.
25. Fye KH, Crowley E, Berger TG, et al.: Celecoxib-induced sweet's syndrome. J Am Acad Dermatol 2001, 45:300-302.
26. Bonnel RA, Villalba ML Karwoski CB, et al.: Aseptic meningitis associated with rofecoxib. Arch Intern Med 2002, 162;713-715.
27. Lund BC, Neiman RF: Visual disturbance associated with celecoxib. Pharmacotherapy 2001, 21:114-115.
28. Lard LR, Visser H, Speyer I: Eady versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451.
29. Mottonen T, Hannonen P, Korpela M, et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002, 46:894-898. • Lard [28] and Mottonen have conducted important analyses to examine whether early initiation of DMARD therapy benefits patients.
30. American College of Rheumatology: Guidelines for the Management of Rheumatoid Arthritis. 2002 Update. Arthritis Rheumat 2002, 46:328-346.
31. Moreland LW, Cohen SB, Baumgartner SW: Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001, 28:1238-1244.
32. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Mec 2001, 345:1098-104.
33. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
34. American College of Rheumatology: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. Arthritis Rheum 2001, 44:1496-1503.
35. De Nijs RNJ, Jacobs WG, Bijlsman JWJ, et al.: Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 2001, 40:1375-1383.
36. Cacoub P, Chemlal K, Khalifa P, et al.: Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol 2001, 28:2474-2479.
37. Oinuma K, Harada Y, Nawata Y, et al.: Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001, 60:1145-1148.
38. Taggart H, Bolognese M, Lindsay R, et al.: Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262-270.
39. Donohue JG, Chan A, Andrade SE, et al.: Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002, 162:936-942. • These analyses have clinical importance and show careful control of potential confounders.
40. Illei GG, Austin Ill HA, Crane M, et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
41. Mok CC, Kwan CT, Chan KW, et al.: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002, 46:1003-1013.
42. Cherin P, Pelletier S, Teixeira A, et al.: Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis. Arthritis Rheum 2002, 46:467-474.
43. Sambo P, Amico D, Giacomelli R, et al.: Intravenous n-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001, 28:2257-2262.